BMS logs three FDA label approvals and posts results for melanoma combo trialSep 2Weekly roundup, 5 itemsadagrasibBristol Myers Squibb
Replimune's TUDRIQEV wins FDA accelerated approval, launch set within 60 daysAug 14Quarterly updateReplimune, Inc.
Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer dataAug 5Quarterly updateXencor, Inc.XMAB819
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
Scancell to merge with Neuphoria and list on Nasdaq, plans up to $89 million financingJul 23PartnershipNeuphoria Therapeutics Inc.
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin
Replimune's RP1 BLA resubmission accepted by FDA; adcomm expected late JulyJun 29Quarterly updateReplimune, Inc.
Sign inSign in